Human_JJ
immunodeficiency_NN
virus_NN
type-2_JJ
gene_NN
expression_NN
:_:
two_CD
enhancers_NNS
and_CC
their_PRP$
activation_NN
by_IN
T-cell_NN
activators_NNS
._.

The_DT
human_JJ
immunodeficiency_NN
viruses_NNS
-LRB-_-LRB-
HIVs_NN
-RRB-_-RRB-
may_MD
include_VB
a_DT
spectrum_NN
of_IN
retroviruses_NNS
with_IN
varying_VBG
potential_NN
to_TO
infect_VB
their_PRP$
host_NN
,_,
undergo_VB
long_JJ
periods_NNS
of_IN
latent_JJ
infection_NN
,_,
and_CC
induce_VB
pathology_NN
._.

Since_IN
expression_NN
of_IN
the_DT
viruses_NNS
is_VBZ
in_IN
large_JJ
part_NN
regulated_VBN
by_IN
the_DT
sequence_NN
elements_NNS
in_IN
their_PRP$
long_JJ
terminal_JJ
repeats_NNS
-LRB-_-LRB-
LTRs_NNS
-RRB-_-RRB-
,_,
this_DT
study_NN
was_VBD
directed_VBN
to_TO
an_DT
analysis_NN
of_IN
the_DT
regulatory_JJ
elements_NNS
in_IN
the_DT
HIV-2_NN
LTR_NN
._.

The_DT
HIV-2_NN
LTR_NN
was_VBD
found_VBN
to_TO
contain_VB
two_CD
enhancers_NNS
._.

One_CD
of_IN
these_DT
enhancers_NNS
is_VBZ
,_,
in_IN
part_NN
,_,
identical_JJ
to_TO
the_DT
HIV-1_NN
enhancer_NN
._.

This_DT
enhancer_NN
in_IN
HIV-1_NN
is_VBZ
the_DT
T-cell_NN
activation_NN
response_NN
element_NN
;_:
in_IN
HIV-2_NN
,_,
however_RB
,_,
it_PRP
is_VBZ
the_DT
second_JJ
enhancer_NN
that_WDT
is_VBZ
mainly_RB
responsible_JJ
for_IN
activation_NN
in_IN
response_NN
to_TO
T-cell_NN
activators_NNS
._.

The_DT
second_JJ
enhancer_NN
interacts_VBZ
with_IN
two_CD
nuclear_JJ
binding_NN
proteins_NNS
-LRB-_-LRB-
85_CD
kD_NN
and_CC
27_CD
kD_NN
mobility_NN
-RRB-_-RRB-
that_WDT
appear_VBP
to_TO
be_VB
required_VBN
for_IN
optimal_JJ
enhancer_NN
function_NN
and_CC
activation_NN
._.

Observations_NNS
such_JJ
as_IN
these_DT
encourage_VBP
the_DT
speculation_NN
that_IN
there_EX
may_MD
be_VB
subtle_JJ
differences_NNS
in_IN
the_DT
regulation_NN
of_IN
HIV-1_NN
and_CC
HIV-2_NN
expression_NN
that_WDT
may_MD
be_VB
relevant_JJ
to_TO
the_DT
possible_JJ
longer_JJR
latency_NN
and_CC
reduced_VBN
pathogenicity_NN
of_IN
HIV-2_NN
._.

